INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date:Thursday, June 26, 2025Time:4:00 pm Eastern TimeLocation:Zoom Teleconference

Institution: AdventHealth Orlando, Orlando, FL

Principal Investigator: Tarek Mekhail, MD

Protocol: Merck Sharp & Dohme LLC, V940-002

NCT Number: NCT05933577

Meeting Type: Continuing Review of Protocol and Site

Title: A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-

Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage

II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

1. Call to order:

The Meeting was called to order at 4:22 pm Eastern Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Three voting members were present, including one local member unaffiliated with the institution. Also present were three Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

An Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 3 NO: 0 ABSTAIN: 0

7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair provided an overview of changes since the last review.

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-1 containment facilities and practices plus Standard Precautions** are required for V940 because the study agent consists of synthetic mRNA administered via intramuscular injection. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of V940 locally**, provided that other biosafety criteria for study closure are also met. The Committee reaffirmed this determination.

9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

Х	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 3 NO: 0

1 of 2

ABSTAIN: 0


INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Points of Discussion:

 An Institutional Representative confirmed that safety needles will be used to prepare and dose the study agent. The Committee recommended that Biosafety SOP Section 3.3 be revised to indicate that safety needles will be used.



3. The Committee discussed the Biohazard Sign and noted that it would be acceptable if the Institution wishes to combine all mRNA-based study agents under IBC review onto one sign.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representatives.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

Х	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 3 NO: 0 ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 4:28 pm Eastern Time.